Abstract
Inflammation is emerging as one of the hallmarks of cancer, yet its role in most tumors remains unclear. Whereas a minority of solid tumors are associated with overt inflammation, long-term treatment with non-steroidal anti-inflammatory drugs is remarkably effective in reducing cancer rate and death. This indicates that inflammation might have many as-yet-unrecognized facets, among which an indolent course might be far more prevalent than previously appreciated. In this Review, we explore the various inflammatory processes underlying the development and progression of colorectal cancer and discuss anti-inflammatory means for its prevention and treatment.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / immunology*
-
Adenocarcinoma / prevention & control
-
Adenoma / immunology*
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Carcinogenesis / immunology*
-
Colorectal Neoplasms / drug therapy
-
Colorectal Neoplasms / immunology*
-
Colorectal Neoplasms / prevention & control
-
DNA Damage / immunology
-
Disease Progression
-
Dysbiosis / immunology*
-
Gastrointestinal Microbiome / immunology*
-
Humans
-
Immunity, Innate / immunology
-
Immunity, Mucosal / immunology
-
Inflammation*
-
Inflammatory Bowel Diseases / immunology*
-
Interleukin-1beta / antagonists & inhibitors
-
Intestinal Mucosa / immunology*
-
Janus Kinases / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Receptors, Interleukin-6 / antagonists & inhibitors
-
STAT Transcription Factors / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Interleukin-1beta
-
Programmed Cell Death 1 Receptor
-
Receptors, Interleukin-6
-
STAT Transcription Factors
-
Tumor Necrosis Factor-alpha
-
Janus Kinases